Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

CAR-T for multiple myeloma: practice pearls

Bone Marrow Transplantation volume 60, pages 940–947 (2025)Cite this article

Subjects

Abstract

The CAR-T cell products ciltacabtagene autoleucel and idecabtagene vicleucel have transformed the management of patients with multiple myeloma. Here, we present a practical guide highlighting clinical pearls on the incorporation of CAR-T into clinical practice. Topics addressed include expected outcomes, recommendations for referral timing, bridging therapy, treatment complications, therapeutic sequencing, and management of relapse.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to the full article PDF.

USD 39.95

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Potential etiologies for cytopenia in the post-CAR-T setting.

Similar content being viewed by others

References

  1. Sheykhhasan M, Ahmadieh-Yazdi A, Vicidomini R, Poondla N, Tanzadehpanah H, Dirbaziyan A, et al. CAR T therapies in multiple myeloma: unleashing the future. Cancer Gene Ther. 2024;31:667–86.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. National Comprehenisve Cancer Network. NCCN Guidelines: Multiple Myeloma, Version 4.2024. 2024 [cited 2024 Jul 13]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/myeloma.pdf

  3. Research C for DE and. FDA approves idecabtagene vicleucel for multiple myeloma. FDA. 2021 Jun 11 [cited 2024 Jul 13]; Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-idecabtagene-vicleucel-multiple-myeloma

  4. Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, et al. Idecabtagene Vicleucel in relapsed and Refractory multiple Myeloma. N. Engl J Med. 2021;384:705–16.

    Article  CAS  PubMed  Google Scholar 

  5. Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021;398:314–24.

    Article  CAS  PubMed  Google Scholar 

  6. Cohen AD, Parekh S, Santomasso BD, Gállego Pérez-Larraya J, van de Donk NWCJ, Arnulf B, et al. Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies. Blood Cancer J. 2022;12:1–9.

    Article  Google Scholar 

  7. Ailawadhi S, Shune L, Wong SW, Lin Y, Patel K, Jagannath S. Optimizing the CAR T-cell therapy experience in multiple myeloma: clinical pearls from an expert roundtable. Clin Lymphoma, Myeloma Leuk. 2024;24:e217–25.

    Article  CAS  PubMed  Google Scholar 

  8. Villanueva R, Hansen DK, Tonseth RP, Gage KL, Wei Z, De Avila G, et al. High metabolic tumor volume is associated with higher toxicity and decreased efficacy of BCMA CAR-T cell therapy in multiple myeloma. Blood. 2022;140:10402–4.

    Article  Google Scholar 

  9. Baguet C, Larghero J, Mebarki M. Early predictive factors of failure in autologous CAR T-cell manufacturing and/or efficacy in hematologic malignancies. Blood Adv. 2024;8:337–42.

    Article  CAS  PubMed  Google Scholar 

  10. Jo T, Yoshihara S, Okuyama Y, Fujii K, Henzan T, Kahata K, et al. Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan. Br J Haematol. 2023;202:256–66.

    Article  CAS  PubMed  Google Scholar 

  11. Cancer Network [Internet]. 2024 [cited 2024 Jul 13]. FDA Approves Ide-Cel in Previously Treated Multiple Myeloma. Available from: https://www.cancernetwork.com/view/fda-approves-ide-cel-in-previously-treated-multiple-myeloma

  12. Research C for BE and. CARVYKTI. FDA [Internet]. 2024 Jun 13 [cited 2024 Jul 14]; Available from: https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/carvykti

  13. Package Insert: ABECMA [Internet]. [cited 2024 Jul 13]. Available from: https://www.fda.gov/media/147055/download?attachment

  14. Package Insert: CARVYKTI [Internet]. [cited 2024 Jul 13]. Available from: https://www.fda.gov/media/156560/download

  15. Anderson LD, Dhakal B, Jain T, Oluwole OO, Shah GL, Sidana S, et al. Chimeric Antigen Receptor T cell therapy for myeloma: where are we now and what is needed to move chimeric antigen receptor T cells forward to earlier lines of therapy? Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Transplant Cell Ther, Off Publ Am Soc Transplant Cell Ther. 2024;30:17–37.

    CAS  Google Scholar 

  16. Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol. 2023 May 15 [cited 2024 Jul 14];14. Available from: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2023.1188049/full

  17. Jain MD, Smith M, Shah NN. How I treat refractory CRS and ICANS after CAR T-cell therapy. Blood. 2023;141:2430–42.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Jain T, Olson TS, Locke FL. How I treat cytopenias after CAR T-cell therapy. Blood. 2023;141:2460–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Gutierrez C, Neilan TG, Grover NS. How I approach optimization of patients at risk of cardiac and pulmonary complications after CAR T-cell therapy. Blood. 2023;141:2452–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Geethakumari PR, Ramasamy DP, Dholaria B, Berdeja J, Kansagra A. Balancing quality, cost, and access during delivery of newer cellular and immunotherapy treatments. Curr Hematol Malig Rep. 2021;16:345–56.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Hansen DK, Sidana S, Peres LC, Colin Leitzinger C, Shune L, Shrewsbury A, et al. Idecabtagene Vicleucel for relapsed/refractory multiple myeloma: real-world experience from the myeloma CAR T Consortium. J Clin Oncol. 2023;41:2087–97.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Sidana S, Patel KK, Peres LC, Bansal R, Kocoglu MH, Shune L, et al. Safety and efficacy of standard-of-care ciltacabtagene autoleucel for relapsed/refractory multiple myeloma. Blood. 2025;145:85–97.

    Article  CAS  PubMed  Google Scholar 

  23. Santomasso BD, Gust J, Perna F. How I treat unique and difficult-to-manage cases of CAR T-cell therapy–associated neurotoxicity. Blood. 2023;141:2443–51.

    CAS  PubMed  PubMed Central  Google Scholar 

  24. Bhaskar ST, Dholaria BR, Sengsayadeth SM, Savani BN, Oluwole OO. Role of bridging therapy during chimeric antigen receptor T cell therapy. EJHaem. 2021;3:39–45.

    Article  PubMed  PubMed Central  Google Scholar 

  25. St Martin Y, Franz JK, Agha ME, Lazarus HM. Failure of CAR-T cell therapy in relapsed and refractory large cell lymphoma and multiple myeloma: An urgent unmet need. Blood Rev. 2023;60:101095.

    Article  Google Scholar 

  26. Levine BL, Miskin J, Wonnacott K, Keir C. Global manufacturing of CAR T cell therapy. Mol Ther Methods Clin Dev. 2017;4:92–101.

    Article  CAS  PubMed  Google Scholar 

  27. Ayala Ceja M, Khericha M, Harris CM, Puig-Saus C, Chen YY. CAR-T cell manufacturing: Major process parameters and next-generation strategies. J Exp Med. 2024;221:e20230903.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Al Hadidi S, Szabo A, Esselmann J, Hammons L, Hussain M, Ogunsesan Y, et al. Clinical outcome of patients with relapsed refractory multiple myeloma listed for BCMA directed commercial CAR-T therapy. Bone Marrow Transpl. 2023;58:443–5.

    Article  Google Scholar 

  29. Kourelis T, Bansal R, Berdeja J, Siegel D, Patel K, Mailankody S, et al. Ethical challenges with multiple myeloma BCMA chimeric antigen receptor T cell slot allocation: a multi-institution experience. Transpl Cell Ther. 2023;29:255–8.

    Article  Google Scholar 

  30. Bowden B, Ciccone D, Salmon J, Alegria V, Kallenbach L, De Braganca KC. Using real-world remanufacturing and recollection data to optimize time-to-treatment in patients with out-of-specification Ciltacabtagene Autoleucel. Blood. 2023;142:6918.

    Article  Google Scholar 

  31. Firestone RS, Mailankody S. Current use of CAR T cells to treat multiple myeloma. Hematology. 2023;2023:340–7.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Rodriguez-Otero P, Ailawadhi S, Arnulf B, Patel K, Cavo M, Nooka AK, et al. Ide-cel or standard regimens in relapsed and refractory multiple myeloma. N Engl J Med. 2023;388:1002–14.

  33. Rodriguez-Otero P, Usmani S, Cohen AD, van de Donk NWCJ, Leleu X, Gállego Pérez-Larraya J, et al. International Myeloma Working Group immunotherapy committee consensus guidelines and recommendations for optimal use of T-cell-engaging bispecific antibodies in multiple myeloma. Lancet Oncol. 2024;25:e205–16.

    Article  CAS  PubMed  Google Scholar 

  34. Dhakal B, Akhtar OS, Cowan AJ, Richard S, Friend R, Rees MJ, et al. Talquetamab bridging: Paving the Way to B-cell maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM). Blood. 2024;144:931.

    Article  Google Scholar 

  35. Roddie C, Neill L, Osborne W, Iyengar S, Tholouli E, Irvine D, et al. Effective bridging therapy can improve CD19 CAR-T outcomes while maintaining safety in patients with large B-cell lymphoma. Blood Adv. 2023;7:2872–83.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Shahid S, Ramaswamy K, Flynn J, Mauguen A, Perica K, Park JH, et al. Impact of bridging chemotherapy on clinical outcomes of CD19-Specific CAR T cell therapy in children/young adults with relapsed/refractory B cell acute lymphoblastic leukemia. Transpl Cell Ther. 2022;28:72.e1–72.e8.

    Article  CAS  Google Scholar 

  37. Costa BA, Flynn J, Nishimura N, Devlin SM, Farzana T, Rajeeve S, et al. Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma. Blood Cancer J. 2024;14:84.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, et al. Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome. Transplant Cell Ther. 2023;29:438.e1–438.e16.

    Article  PubMed  Google Scholar 

  39. Wohlfarth P, Agis H, Gualdoni GA, Weber J, Staudinger T, Schellongowski P, et al. Interleukin 1 Receptor Antagonist Anakinra, Intravenous Immunoglobulin, and Corticosteroids in the Management of Critically Ill Adult Patients With Hemophagocytic Lymphohistiocytosis. J Intensive Care Med. 2019;34:723–31.

    Article  PubMed  Google Scholar 

  40. Wang J, Wang Y, Wu L, Wang X, Jin Z, Gao Z, et al. Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis. Haematologica. 2020;105:e210–2.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Wang J, Zhang R, Wu X, Li F, Yang H, Liu L, et al. Ruxolitinib-combined doxorubicin-etoposide-methylprednisolone regimen as a salvage therapy for refractory/relapsed haemophagocytic lymphohistiocytosis: a single-arm, multicentre, phase 2 trial. Br J Haematol. 2021;193:761–8.

    Article  CAS  PubMed  Google Scholar 

  42. Fortuna GG, Banerjee R, Savid-Frontera C, Song J, Morán-Segura CM, Nguyen JV, et al. Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma. Blood Cancer J. 2024;14:1–8.

    Article  Google Scholar 

  43. ONS 2024: Incidence and Management of Cranial Nerve Impairments in Patients With Multiple Myeloma Treated With Ciltacabtagene Autoleucel in CARTITUDE Studies [Internet]. [cited 2025 Jan 22]. Available from: https://clin.larvol.com/abstract-detail/ONS%202024/70145524

  44. Karschnia P, Miller KC, Yee AJ, Rejeski K, Johnson PC, Raje N, et al. Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells. Blood. 2023;142:1243–8.

    Article  CAS  PubMed  Google Scholar 

  45. Van Oekelen O, Aleman A, Upadhyaya B, Schnakenberg S, Madduri D, Gavane S, et al. Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy. Nat Med. 2021;27:2099–103.

    Article  PubMed  PubMed Central  Google Scholar 

  46. Mejia Saldarriaga M, Pan D, Unkenholz C, Mouhieddine TH, Velez-Hernandez JE, Engles K, et al. Absolute lymphocyte count after BCMA CAR-T therapy is a predictor of response and outcomes in relapsed multiple myeloma. Blood Adv. 2024;8:3859–69.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi A, Barba P, et al. Immune effector cell–associated hematotoxicity: EHA/EBMT consensus grading and best practice recommendations. Blood. 2023;142:865–77.

    Article  CAS  PubMed  Google Scholar 

  48. Rejeski K, Perez A, Sesques P, Hoster E, Berger C, Jentzsch L, et al. CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma. Blood. 2021;138:2499–513.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Rejeski K, Hansen DK, Bansal R, Sesques P, Ailawadhi S, Logue JM, et al. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma. J Hematol Oncol. 2023;16:88.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Davis JA, Sborov DW, Wesson W, Julian K, Abdallah AO, McGuirk JP, et al. Efficacy and Safety of CD34+ Stem Cell Boost for Delayed Hematopoietic Recovery After BCMA Directed CAR T-cell Therapy. Transplant Cell Ther. 2023;29:567–71.

    Article  CAS  PubMed  Google Scholar 

  51. Wat J, Barmettler S. Hypogammaglobulinemia after Chimeric Antigen Receptor (CAR) T-cell therapy: characteristics, management, and future directions. J Allergy Clin Immunol Pr. 2022;10:460–6.

    Article  CAS  Google Scholar 

  52. Wang Y, Li C, Xia J, Li P, Cao J, Pan B, et al. Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma. Blood Adv. 2021;5:5290–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Lancman G, Parsa K, Kotlarz K, Avery L, Lurie A, Lieberman-Cribbin A, et al. IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies. Blood Cancer Discov. 2023;4:440–51.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Ferreri CJ, Hildebrandt MAT, Hashmi H, Shune LO, McGuirk JP, Sborov DW, et al. Real-world experience of patients with multiple myeloma receiving ide-cel after a prior BCMA-targeted therapy. Blood Cancer J. 2023;13:1–9.

    Article  Google Scholar 

  55. Charting the Course: Sequencing Immunotherapy for Multiple Myeloma | American Society of Clinical Oncology Educational Book [Internet]. [cited 2024 Jul 14]. Available from: https://ascopubs.org/doi/10.1200/EDBK_432204

  56. Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, et al. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021;12:868.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Li W, Zhang B, Cao W, Zhang W, Li T, Liu L, et al. Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing. Exp Hematol Oncol. 2023;12:44.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Patel U, Oluwole OO, Kassim A, Jayani R, Belliveau P, Savani B, et al. Sequencing bispecific antibodies and CAR T cell therapy in multiple myeloma with prior exposure to BCMA-targeted therapies. JCO. 2023;41:e20049–e20049.

    Article  Google Scholar 

Download references

Funding

Citiius, Gamida cell, Incyte. Advisory Board Membership: Abvie, CRISPR, Allogene, Astra Zeneca, BeiGene.

Author information

Authors and Affiliations

  1. Division of Hematology, Oncology, and Transplantation, University of Minnesota, Minneapolis, USA

    Daniel O’Leary & Veronika Bachanova

Authors
  1. Daniel O’Leary
    View author publications

    Search author on:PubMed Google Scholar

  2. Veronika Bachanova
    View author publications

    Search author on:PubMed Google Scholar

Contributions

DO researched and wrote the manuscript. VB edited and helped write the manuscript.

Corresponding author

Correspondence to Daniel O’Leary.

Ethics declarations

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

O’Leary, D., Bachanova, V. CAR-T for multiple myeloma: practice pearls. Bone Marrow Transplant 60, 940–947 (2025). https://doi.org/10.1038/s41409-025-02582-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41409-025-02582-6

Search

Advanced search

Quick links